ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
외음부암 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 치료 옵션에 대한 수요 증가, 표적 치료제 채택 증가, 조기 암 진단에 대한 집중 확대, 맞춤형 의료의 중시, 스크리닝 프로그램의 확대 등에 기인한다고 생각됩니다. 이 기간의 주요 동향으로서는 표적 요법이나 병용 요법의 진보, 맞춤형 의료의 역할의 증대, 전략적 협동, 로봇 지원 수술의 채택 등을 들 수 있습니다.
종양학 연구 및 의료 투자 증가는 향후 몇 년 동안 이 시장의 성장을 이끌 것으로 예측됩니다. 치료의 진보, 혁신적인 치료법에 대한 수요, 임상시험 확대, 정부 및 민간 자금 제공 이니셔티브, 표적요법과 면역요법의 개발 등이 이러한 투자의 급증에 기여하고 있습니다. 보다 효과적인 약제의 임상시험에 대한 자금 제공, 소아암 치료의 인프라 강화, 질환의 생물학적 성질과 진행의 이해를 위한 혁신적 연구의 육성 등, 조사 연구를 지원하고 있습니다. 2024년 5월 인도에 본사를 둔 첨단 분석 전문 정보 기술 회사인 IQVIA는 2023년의 세계의 암 치료 지출이 2022년부터 250억 달러 증가해 2,230억 달러에 이르렀고, 2028년에는 4,090억 달러에 이를 것으로 예측하고 있다고 보고했습니다.
또한, 맞춤형 의료가 중시되게 되어 있는 것도 외음부암 시장의 확대에 기여할 것으로 예측됩니다. 작용을 최소화할 수 있기 때문에 지지를 모으고 있습니다. 외음부암의 경우, 맞춤형 의료는 환자의 유전자 프로파일에 근거해 치료를 최적화해, 치료 성적의 향상과 부작용의 경감으로 연결됩니다.
2024년 2월 미국 비영리 단체인 개인 맞춤 의학 연합(Personalized Medicine Coalition)은 2023년 FDA가 희소질환 환자를 위한 신규 개인화 치료를 16건 승인했고, 이는 2022년 6건에서 증가했다고 보고했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 외음부암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 외음부암 시장 : 성장률 분석
세계의 외음부암 시장 실적 : 규모와 성장, 2019-2024
세계의 외음부암 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 외음부암 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 외음부암 시장 : 암유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
외음부 편평상피암
외음부 흑색종
선암암
기저세포암
세계의 외음부암 시장 : 치료유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
화학요법
수술
레이저 수술
절제
외음부피박절제술
근치적 외음절제술
방사선치료
생물학적 요법
세계의 외음부암 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
온라인 채널
오프라인 채널
세계의 외음부암 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 및 진료소
조사·학술 기관
기타 최종 사용자
세계의 외음부암 시장 : 외음부 편평상피암유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
각화 편평상피암
비각화 편평상피암
사마귀성 암
세계의 외음부암 시장 : 외음부 흑색종유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
점막 흑색종
말단 흑자형 흑색종
결절성 흑색종
세계의 외음부암 시장 : 선암유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
발트린 선암
유선외 파젯병 관련 선암
땀샘선암
세계의 외음부암 시장 : 기저세포암유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
표재성 기저세포암
결절성 기저세포암
경화성 기저 세포암
제7장 지역별/국가별 분석
세계의 외음부암 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 외음부암 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
외음부암 시장 : 경쟁 구도
외음부암 시장 : 기업 프로파일
F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
Merck And Co. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
Amgen Inc.
Siemens Healthineers
Teva Pharmaceutical
Regeneron Pharmaceuticals, Inc.
Intuitive Surgical Operations Inc.
Sun Pharmaceuticals Ltd.
Genentech Inc
Varian Medical Systems Inc.
Ono Pharmaceuticals Co. Ltd.
Elekta AB
Accuray Incorporated.
Xencor
Nordion Inc.
ISA Pharmaceuticals BV
Alpha Tau Medical Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
외음부암 시장(2029년) : 새로운 기회를 제공하는 국가
외음부암 시장(2029년) : 새로운 기회를 제공하는 부문
외음부암 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Vulvar cancer is a type of cancer that develops in the vulva, the external part of the female genitalia. It usually originates in the skin or tissues of the vulva and may affect the labia, clitoris, or vaginal opening. The most common type is squamous cell carcinoma, which is often associated with human papillomavirus (HPV) infection. Symptoms can include itching, pain, and visible growths or sores on the vulva.
The main types of vulvar cancer include vulvar squamous cell carcinoma (SCC), vulvar melanoma, adenocarcinoma, and basal cell carcinoma. Vulvar SCC originates in the squamous cells of the vulva and is the most prevalent form. Treatment options include chemotherapy, surgery, laser surgery, excision, skinning vulvectomy, radical vulvectomy, radiation therapy, and biologic therapy. These treatments are distributed through online and offline channels and are utilized by various end users, including hospitals and clinics, research and academic institutes, and other healthcare facilities.
The vulvar cancer market research report is one of a series of new reports from The Business Research Company that provides vulvar cancer market statistics, including vulvar cancer industry global market size, regional shares, competitors with a vulvar cancer market share, detailed vulvar cancer market segments, market trends and opportunities, and any further data you may need to thrive in the vulvar cancer industry. This vulvar cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vulvar cancer market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising adoption of immunotherapy, an increasing incidence of vulvar cancer, greater investments in research and development, expanding government initiatives, and the growing use of HPV vaccines.
The vulvar cancer market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing demand for therapeutic options, the rising adoption of targeted therapies, a greater focus on early cancer diagnosis, an emphasis on personalized medicine, and the expansion of screening programs. Key trends during this period include advancements in targeted and combination therapies, the growing role of personalized medicine, strategic collaborations, and the adoption of robotic-assisted surgery.
The increasing investments in oncology research and medicine are expected to drive the growth of the vulvar cancer market in the coming years. These investments, made by governments, pharmaceutical companies, research institutions, and private investors, aim to advance the understanding, prevention, diagnosis, and treatment of cancer. The rising global cancer burden, advancements in precision medicine, demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments contribute to this surge in investments. These financial contributions support vulvar cancer research by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to understand the disease's biology and progression. For example, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, reflecting a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, increasing investments in oncology research and medicine continue to drive the vulvar cancer market.
The growing emphasis on personalized medicine is also expected to contribute to the expansion of the vulvar cancer market. Personalized medicine involves tailoring medical treatments to individual patients based on genetic, environmental, and lifestyle factors. This approach is gaining traction as it enhances treatment effectiveness and minimizes adverse effects by addressing patient-specific differences. In the case of vulvar cancer, personalized medicine helps optimize treatments based on a patient's genetic profile, leading to improved outcomes and reduced side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. The increasing focus on personalized medicine is, therefore, contributing to the growth of the vulvar cancer market.
Leading companies in the vulvar cancer market are prioritizing innovations in cancer therapy, including advancements in alpha-radiation cancer therapy, to improve treatment efficacy and patient outcomes. Alpha-radiation cancer therapy involves the targeted delivery of alpha particles to tumor cells, causing localized damage to cancerous tissue while minimizing harm to surrounding healthy cells. For instance, in May 2023, Alpha Tau Medical Ltd., an Israel-based company, announced the first use of its Alpha DaRT alpha-radiation cancer therapy to treat squamous cell carcinoma of the vulva. The study, conducted at Addenbrooke's Hospital within the Cambridge University Hospitals NHS Foundation Trust, aims to recruit 10 participants to evaluate the therapy's safety and effectiveness. Alpha DaRT offers a targeted, minimally invasive treatment approach, highlighting its potential as a non-surgical option for vulvar cancer.
Major players in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck and Co., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Siemens Healthineers, Teva Pharmaceutical, Regeneron Pharmaceuticals, Inc., Intuitive Surgical Operations Inc., Sun Pharmaceuticals Ltd., Genentech Inc, Varian Medical Systems Inc., Ono Pharmaceuticals Co. Ltd., Elekta AB, Accuray Incorporated., Xencor, Nordion Inc., ISA Pharmaceuticals BV, Alpha Tau Medical Ltd.
North America was the largest region in the vulvar cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vulvar cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vulvar cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vulvar cancer market consists of revenues earned by entities by providing services such as diagnostic testing, clinical consultations, immunotherapy, targeted therapy, and post-treatment care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvar cancer market also includes sales of pharmaceuticals, immunotherapy drugs, targeted therapy medications, diagnostic kits, and medical devices for tumor detection and monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vulvar Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vulvar cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vulvar cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vulvar cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Cancer Type: Vulvar Squamous Cell Carcinoma; Vulvar Melanoma; Adenocarcinoma; Basal Cell Carcinoma
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vulvar Cancer Market Characteristics
3. Vulvar Cancer Market Trends And Strategies
4. Vulvar Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Vulvar Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Vulvar Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Vulvar Cancer Market Growth Rate Analysis
5.4. Global Vulvar Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Vulvar Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Vulvar Cancer Total Addressable Market (TAM)
6. Vulvar Cancer Market Segmentation
6.1. Global Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vulvar Squamous Cell Carcinoma
Vulvar Melanoma
Adenocarcinoma
Basal Cell Carcinoma
6.2. Global Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Surgery
Laser Surgery
Excision
Skinning Vulvectomy
Radical Vulvectomy
Radiation Therapy
Biologic Therapy
6.3. Global Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Channel
Offline Channel
6.4. Global Vulvar Cancer Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Research And Academic Institutes
Other End Users
6.5. Global Vulvar Cancer Market, Sub-Segmentation Of Vulvar Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Keratinizing Squamous Cell Carcinoma
Non-Keratinizing Squamous Cell Carcinoma
Verrucous Carcinoma
6.6. Global Vulvar Cancer Market, Sub-Segmentation Of Vulvar Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mucosal Melanoma
Acral Lentiginous Melanoma
Nodular Melanoma
6.7. Global Vulvar Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
